-DOCSTART- -X- O
An -X- _ O
outbreak -X- _ O
of -X- _ O
West -X- _ B-Patient
Nile -X- _ I-Patient
Virus -X- _ I-Patient
( -X- _ I-Patient
WNV -X- _ I-Patient
) -X- _ I-Patient
like -X- _ O
the -X- _ O
recent -X- _ O
Ebola -X- _ O
can -X- _ O
be -X- _ O
more -X- _ O
epidemic -X- _ O
and -X- _ O
fatal -X- _ O
to -X- _ O
public -X- _ O
health -X- _ O
throughout -X- _ O
the -X- _ O
world. -X- _ O
WNV -X- _ O
possesses -X- _ O
utmost -X- _ O
threat -X- _ O
as -X- _ O
no -X- _ O
vaccine -X- _ O
or -X- _ O
drug -X- _ O
is -X- _ O
currently -X- _ O
available -X- _ O
for -X- _ O
its -X- _ O
treatment -X- _ O
except -X- _ O
mosquito -X- _ O
control. -X- _ O
The -X- _ O
current -X- _ O
study -X- _ O
applied -X- _ O
the -X- _ O
combined -X- _ O
approach -X- _ O
of -X- _ O
immunoinformatics -X- _ B-Intervention
and -X- _ I-Intervention
pharmacoinformatics -X- _ I-Intervention
to -X- _ I-Intervention
design -X- _ I-Intervention
potential -X- _ I-Intervention
epitope-based -X- _ I-Intervention
vaccines -X- _ I-Intervention
and -X- _ I-Intervention
drug -X- _ I-Intervention
candidates -X- _ I-Intervention
against -X- _ I-Intervention
WNV. -X- _ I-Intervention
By -X- _ O
analyzing -X- _ O
the -X- _ O
whole -X- _ O
proteome -X- _ O
of -X- _ O
2994 -X- _ O
proteins -X- _ O
, -X- _ O
the -X- _ O
WNV -X- _ B-Patient
envelope -X- _ I-Patient
glycoprotein -X- _ I-Patient
was -X- _ O
selected -X- _ O
as -X- _ O
a -X- _ O
therapeutic -X- _ O
target -X- _ O
based -X- _ O
on -X- _ O
its -X- _ O
highest -X- _ O
antigenicity. -X- _ O
After -X- _ O
proper -X- _ O
assessment -X- _ O
“KSFLVHREW” -X- _ B-Outcome
and -X- _ O
“ITPSAPSYT” -X- _ B-Outcome
were -X- _ O
found -X- _ O
to -X- _ O
be -X- _ O
the -X- _ O
most -X- _ O
potential -X- _ O
T -X- _ O
and -X- _ O
B-cell -X- _ O
epitopes -X- _ O
, -X- _ O
respectively. -X- _ O
Besides -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
designed -X- _ O
and -X- _ O
validated -X- _ O
four -X- _ O
novel -X- _ O
drugs -X- _ O
from -X- _ O
a -X- _ O
known -X- _ O
WNV -X- _ O
inhibitor -X- _ O
, -X- _ O
AP30451 -X- _ O
by -X- _ O
adopting -X- _ O
computational -X- _ O
approaches. -X- _ O
Toxicity -X- _ O
assessment -X- _ O
and -X- _ O
drug -X- _ O
score -X- _ O
confirmed -X- _ O
the -X- _ O
effectiveness -X- _ O
of -X- _ O
these -X- _ O
drug -X- _ O
candidates. -X- _ O
This -X- _ O
in -X- _ O
silico -X- _ O
research -X- _ O
might -X- _ O
greatly -X- _ O
facilitate -X- _ O
the -X- _ O
wet -X- _ O
lab -X- _ O
experiments -X- _ O
to -X- _ O
develop -X- _ O
vaccine -X- _ O
and -X- _ O
drug -X- _ O
against -X- _ O
WNV -X- _ O
. -X- _ O

